Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening
Anticancer Research · 2024
DOI: 10.21873/anticanres.17042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Xuan Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, RNA, Long Noncoding, Drug Resistance, Neoplasm, CRISPR-Cas Systems. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan katoshun@juntendo.ac.jp.
Zitieren
APA
Wen, X., Han, M., Hosoya, M., Toshima, R., Onishi, M., Fujii, T., Yamaguchi, S., & Kato, S. (2024). Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening. Anticancer Research. https://doi.org/10.21873/anticanres.17042
Vancouver
Wen X, Han M, Hosoya M, Toshima R, Onishi M, Fujii T, et al. Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening. Anticancer Research. 2024. doi:10.21873/anticanres.17042
BibTeX
@article{Wen2024,
author = {Wen, Xuan and Han, Min and Hosoya, Masaki and Toshima, Rika and Onishi, Mai and Fujii, Tomoaki and Yamaguchi, Shigeo and Kato, Shunsuke},
title = {Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17042}
}
EUVIMED